HK46996A - Use of naftopidil for the treatment of dysuria caused by benign prostate hypertrophy - Google Patents

Use of naftopidil for the treatment of dysuria caused by benign prostate hypertrophy Download PDF

Info

Publication number
HK46996A
HK46996A HK46996A HK46996A HK46996A HK 46996 A HK46996 A HK 46996A HK 46996 A HK46996 A HK 46996A HK 46996 A HK46996 A HK 46996A HK 46996 A HK46996 A HK 46996A
Authority
HK
Hong Kong
Prior art keywords
treatment
naftopidil
prostate hypertrophy
benign prostate
dysuria
Prior art date
Application number
HK46996A
Other languages
German (de)
English (en)
Inventor
Dr Med Vet Sponer Gisbert
Reicke Ulrich
Dr Phil Nelboeck-Hochstetter Michael
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6382247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK46996(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of HK46996A publication Critical patent/HK46996A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Claims (2)

  1. Utilisation de la 1-(2-méthoxyphényl)-4-[3-(naphtyl-1-yl-oxy)-2-hydroxy-propyl]-pipérazine, ou de ses sels pharmaceutiquement acceptables, pour la préparation de médicaments destinés au traitement de la dysurie dans l'hypertrophie de la prostate.
  2. Composition destinée à l'administration par voie orale, contenant, comme substance active, la 1-(2-méthoxyphényl)-4-[3-(naphtyl-1-yl-oxy)-2-hydroxy-propyl]-pipérazine, caractérisée en ce que la prise unitaire contient la substance active en une quantité de 10-50 mg, avec les supports et adjuvants usuels.
HK46996A 1989-06-07 1996-03-14 Use of naftopidil for the treatment of dysuria caused by benign prostate hypertrophy HK46996A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3918543A DE3918543A1 (de) 1989-06-07 1989-06-07 Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie

Publications (1)

Publication Number Publication Date
HK46996A true HK46996A (en) 1996-03-22

Family

ID=6382247

Family Applications (1)

Application Number Title Priority Date Filing Date
HK46996A HK46996A (en) 1989-06-07 1996-03-14 Use of naftopidil for the treatment of dysuria caused by benign prostate hypertrophy

Country Status (19)

Country Link
US (1) US5026706A (fr)
EP (1) EP0401653B1 (fr)
JP (1) JPH062673B2 (fr)
KR (1) KR0131452B1 (fr)
AT (1) ATE84416T1 (fr)
AU (1) AU625766B2 (fr)
CA (1) CA2017619C (fr)
DD (1) DD294864A5 (fr)
DE (2) DE3918543A1 (fr)
DK (1) DK0401653T3 (fr)
ES (1) ES2054147T3 (fr)
GR (1) GR3007328T3 (fr)
HK (1) HK46996A (fr)
HU (1) HU206976B (fr)
IE (1) IE62937B1 (fr)
IL (1) IL94601A (fr)
PH (1) PH26690A (fr)
PT (1) PT94268B (fr)
ZA (1) ZA904338B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474994A (en) * 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
IT1254469B (it) * 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
TW536402B (en) 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
AU7736300A (en) 1999-09-30 2001-04-30 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
BR102012000187A2 (pt) * 2012-01-05 2018-04-10 Univ Rio De Janeiro Derivados n-fenilpiperazínicos antagonistas de adrenoceptores a1a, a1d e de receptores 5-ht1a no tratamento da hiperplasia prostática benigna, composições farmacêuticas contendo os mesmos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL175059C (nl) * 1974-02-23 Boehringer Mannheim Gmbh Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.

Also Published As

Publication number Publication date
IL94601A0 (en) 1991-04-15
HUT54494A (en) 1991-03-28
HU903515D0 (en) 1990-10-28
EP0401653A2 (fr) 1990-12-12
IL94601A (en) 1994-06-24
AU625766B2 (en) 1992-07-16
DE59000748D1 (de) 1993-02-25
ATE84416T1 (de) 1993-01-15
CA2017619A1 (fr) 1990-12-07
EP0401653B1 (fr) 1993-01-13
DK0401653T3 (da) 1993-03-29
PT94268B (pt) 1997-01-31
JPH062673B2 (ja) 1994-01-12
PT94268A (pt) 1991-02-08
PH26690A (en) 1992-09-15
IE902014L (en) 1990-12-07
GR3007328T3 (fr) 1993-07-30
JPH0324014A (ja) 1991-02-01
EP0401653A3 (fr) 1991-07-17
US5026706A (en) 1991-06-25
KR910000152A (ko) 1991-01-29
DD294864A5 (de) 1991-10-17
IE62937B1 (en) 1995-03-08
ZA904338B (en) 1991-03-27
DE3918543C2 (fr) 1991-06-06
HU206976B (en) 1993-03-01
KR0131452B1 (ko) 1998-04-17
CA2017619C (fr) 1995-06-20
ES2054147T3 (es) 1994-08-01
AU5628290A (en) 1990-12-13
DE3918543A1 (de) 1990-12-13

Similar Documents

Publication Publication Date Title
EP1363625A1 (fr) Combinaisons de medicaments (p. ex. un benzimidazole et pentamidine) dans le traitement de troubles neoplasiques
Estes et al. Gastric ulcer perforation associated with the use of injectable ketorolac
Offerhaus Drugs for the elderly
KR0131452B1 (ko) 양성 전립선 비대증 경우의 배뇨장애 치료용 나프토피딜
US4559326A (en) Antiinflammatory compositions and methods
JPH07242560A (ja) 抗菌剤
Nair et al. Dopamine and schizophrenia: A reappraisal in the light of clinical studies with clozapine
Pyle et al. Clinical implications of drugs taken by our patients
Day et al. Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates
Bissada et al. Urologic manifestations of drug therapy
Chiverton et al. Pharmacokinetics and pharmacodynamics of treatments for peptic ulcer disease in the elderly.
JP4706174B2 (ja) α−グルコシダーゼ阻害剤
Siris et al. The problem of psychopharmacotherapy in the medically ill
US4727087A (en) Pharmaceutical composition and method of treatment
KR102251360B1 (ko) 오로볼을 함유하는 설사 개선용 식품 조성물 및 예방 또는 치료용 약학 조성물
Herbai et al. Normalization of hypercalcaemia of primary hyperparathyroidism by treatment with methallenestril, a synthetic oestrogen with low oestrogenicity
BECTUN stands out... ll ‘
CN105997962A (zh) 辅酶q10在治疗周期性麻痹疾病中的应用
Merck & Co et al. The Merck Manual of Diagnosis and Therapy
BEGTON MULTI FIT SYRINGE
VALCOURT Study of excretion of 5-hydroxyindoleacetic acid in mental patients
NZ245673A (en) Use of naftopidil [ie 1-(2-methoxyphenyl)-4-[3-(naphth-1-yloxy)-2-hydroxypropyl]piperazine] to prepare a medicament for the treatment of dysuria
Bagadia et al. Fluphenazine Enanthate Injections in Schizophrenia-A Clinical Trial in 50 Cases
YFALTERS ALDAC TAZ IDE
WO1997023477A1 (fr) Derives de dibenzothiepine et compositions pharmaceutiques

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090530